00000nam 2200000za 4500 9.833914 CaOODSP 20221107150323 cr ||||||||||| 170327s2016 oncd os f000 0 eng d CaOODSP eng eng fre n-cn--- H82-23/2016-PDF The use of diabetes drugs in Canadian drug plans [electronic resource] = Utilisation des médicaments contre le dibète dans les régimes publics d'assurance-médicaments du Canada. Utilisation des médicaments contre le dibète dans les régimes publics d'assurance-médicaments du Canada [Ottawa] : Patented Medicine Prices Review Board, [2016] [1] p. : col. charts Caption title. At head of title: National Prescription Drug Utilization Information System. "The cost of diabetes treatment has been rapidly increasing in Canada in recent years. While the growing prevalence of the disease is a contributing factor, more expensive treatments have been a major cost driver, especially given the uptake in new, higher-cost drugs. This study analyzes these issues from the perspective of Canadian public drug plans, and provides insight into the actual use of the newer and higher-cost diabetes drugs and their associated cost pressures. Results are presented for all public drug plans participating in NPDUIS: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and Health Canada’s Non-Insured Health Benefits drug plan. This analysis will support policy decision makers and the health technology assessment community in determining the future impact of diabetes treatments on their plans." Text in English and French. gccst Diabetes gccst Drug insurance gccst Prescription drugs gccst Prices Canada. Patented Medicine Prices Review Board. National Prescription Drug Utilization Information System (Canada) The use of diabetes drugs in Canadian public drug plans fre (CaOODSP)9.833915 PDF 351 KB https://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-23-2016.pdf